| 6.8005 0.011 (0.15%) | 06-10 12:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.54 | 1-year : | 12.35 |
| Resists | First : | 9.02 | Second : | 10.57 |
| Pivot price | 7.3  |
|||
| Supports | First : | 6.52 | Second : | 5.42 |
| MAs | MA(5) : | 6.88  |
MA(20) : | 7.28 |
| MA(100) : | 11.13 |
MA(250) : | 23.4 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 14.4 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 50.4 | Low : | 6.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LENZ ] has closed above bottom band by 12.6%. Bollinger Bands are 60.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.03 - 7.07 | 7.07 - 7.11 |
| Low: | 6.42 - 6.47 | 6.47 - 6.52 |
| Close: | 6.72 - 6.79 | 6.79 - 6.86 |
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Mon, 08 Jun 2026
LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Proactive financial news
Tue, 26 May 2026
Eye drop company LENZ heads to three investor conferences in June - Stock Titan
Sat, 16 May 2026
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade - Yahoo Finance
Thu, 14 May 2026
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Mon, 11 May 2026
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - LENZ Therapeutics
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 1.848e+007 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 9,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1798e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 321.6 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 2.099e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -29.77 |
| EBITDA (p.s.) | 1.16766e+007 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.23 |
| Price to Cash Flow | 1.42 |
| Dividend | 0 |
| Forward Dividend | 1.11e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2026-07-21 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|